Novavax, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVAX research report →
Range $8 – $8
Price Chart
About the company
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial.
- CEO
- John Charles Jacobs
- IPO
- 1995
- Employees
- 749
- HQ
- Gaithersburg, MD, US
Get TickerSpark's AI analysis on NVAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.23B
- P/E
- -16.24
- Fwd P/E
- 4.89
- PEG
- 0.25
- P/S
- 2.99
- P/B
- -5.68
- EV/EBITDA
- -36.44
- Div Yield
- 0.00%
- Gross Margin
- 77.25%
- Op Margin
- -19.58%
- Net Margin
- -18.64%
- ROE
- 45.13%
- ROIC
- -14.40%
Latest fiscal year · YoY change
- Revenue
- $1.12B+64.7%
- Gross Profit
- $1.05B+119.5%
- Op Income
- $563.27M
- Net Income
- $440.30M+334.8%
- EPS
- $2.72+321.1%
- OCF Growth
- -180.3%
- FCF Growth
- -149.4%
- 52W High
- $13.39
- 52W Low
- $6.25
- 50D MA
- $10.38
- 200D MA
- $9.32
- Beta
- 2.72
- RSI (14)
- 32
- Avg Volume
- 6.76M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Novavax posted a smaller third-quarter loss, raised full-year 2026 revenue guidance on a Sanofi milestone and partner demand, and reiterated a long runway to further milestones and potential profitability.· November 5, 2026
- Q3 revenue was $68 million versus $70 million a year ago, and net loss narrowed to $31 million from $202 million last year.
- Novavax booked a $125 million Sanofi milestone after Sanofi began its phase III flu-COVID combo trial in Europe; an additional $75 million is expected on tech transfer completion in mid-2027.
- Full-year 2026 adjusted total revenue guidance was raised to $400 million midpoint ($385 million-$415 million), and combined non-GAAP R&D/SG&A guidance was reiterated at $325 million midpoint.
- Management said the company ended Q3 with $676 million in cash and accounts receivable and expects cash runway into 2029.
- R&D focus remains on data generation for Matrix-M, partner expansion, and advancing a C. diff candidate that could enter the clinic as early as 2027.
Third-quarter 2026 total revenue was $68 million, down from $70 million in the prior year. Net loss was $31 million versus a $202 million net loss in the prior-year quarter, an improvement of $171 million year over year. Management said Q3 GAAP R&D and SG&A were reduced by 41% year over year, with GAAP R&D down $46 million and 47%. The company ended the quarter with $676 million in cash and accounts receivable. For full-year 2026, Novavax raised adjusted total revenue guidance by $145 million to $400 million at midpoint, with a range of $385 million to $415 million. The increase was driven by the $125 million Sanofi CIC milestone, a $5 million increase to Nuvaxovid product sales, a $5 million increase to adjuvant supply sales, and a $10 million increase to adjusted licensing royalties and other. Novavax improved full-year 2026 combined GAAP R&D and SG&A guidance by $5 million to $385 million midpoint, while reiterating non-GAAP combined R&D and SG&A at $325 million midpoint, within a $315 million-$335 million range.
John Jacobs framed the quarter as progress across Novavax's three pillars: partnering the technology, capital-efficient R&D, and a lean operating model. He emphasized that the company is building a broader portfolio of opportunities across infectious disease and potentially oncology, with Matrix-M and partner relationships as the core of long-term value creation. His tone was upbeat but disciplined, repeatedly stressing focus, selectivity, and the importance of converting data into partnerships.
Jim Kelly led with the company’s financial discipline and the impact of the Sanofi milestone and partner revenue on the outlook. He highlighted Q3 revenue of $68 million, the $31 million net loss, the $676 million in cash and accounts receivable, and a 41% year-over-year reduction in GAAP R&D and SG&A. He also said Novavax now expects the $75 million Sanofi tech transfer milestone in Q3 2027, expects the $225 million U.S. CIC launch milestone to remain a key driver of future non-GAAP profitability timing, and is targeting non-GAAP R&D and SG&A of $150 million-$200 million by 2028.
Analysts focused on three themes: the outlook for the 2026/2027 COVID season, the path from MTAs to paid licenses, and the C. diff and oncology pipelines. Management said U.S. COVID doses are trending at 94% of prior year season-to-date and more recently above 110% weekly, while Sanofi’s pilots are showing encouraging share and reorders. On MTAs, management said there is strong interest but no one-size-fits-all path to monetization; on C. diff, they said the lead candidate is selected, preclinical data are encouraging, and the next major step is entering the clinic. They also said oncology work is still early and could include both off-the-shelf and personalized approaches.
The call pointed to multiple potential catalysts: the $125 million Sanofi milestone already earned, another $75 million expected in 2027, and a possible $225 million U.S. CIC launch milestone later if the program reaches market. Management also said Nuvaxovid demand appears to be stabilizing in the U.S. and growing in select international markets, while Takeda’s Japan business showed momentum last season. On top of that, the company is expanding Matrix-M into new partnership discussions and advancing a C. diff candidate toward the clinic.
A lot of the upside still depends on partner execution, especially Sanofi’s future clinical and regulatory progress, which Novavax cannot control and does not fully see. Management also said R&D reimbursement and Sanofi amortization will shrink materially in 2027, and that some 2027 restructuring could bring up to $35 million of non-cash fixed-asset write-offs. The C. diff and oncology programs are still early, with clinical data still ahead, so their value remains unproven.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.6%
- Shares Outstanding
- 165.01M
- Float Shares
- 146.28M
of shares held by institutions
299 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NVAX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 15.59M | ▲ 1.65M |
| Vanguard Group Inc | 15.47M | ▲ 275.80K |
| Shah Capital Management | 12.17M | ▼ 1.99M |
| State Street Corp | 8.83M | ▼ 2.91M |
| Vanguard Portfolio Management LLC | 7.25M | ▼ 358.64K |
| Vanguard Capital Management LLC | 7.23M | ▼ 25.15K |
| Sanofi | 6.88M | 0 |
| D. E. Shaw & Co., Inc. | 5.73M | ▲ 81.56K |
| Two Sigma Investments, LP | 5.51M | ▲ 1.42M |
| Geode Capital Management, LLC | 4.23M | ▲ 23.20K |
| Coatue Management LLC | 3.84M | 0 |
| Bank Of America Corp | 3.79M | ▲ 376.10K |
Held by 274 ETFs
Biggest fund positions in NVAX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 26 | Rodgers Richard J | other | 18,880 |
| Jun 18, 26 | Rodgers Richard J | other | 21,270 |
| Jun 18, 26 | Rodgers Richard J | other | 14,180 |
| Jun 20, 26 | Rodgers Richard J | other | 18,880 |
| Jun 20, 26 | King Rachel K. | other | 18,880 |
| Jun 18, 26 | King Rachel K. | other | 21,270 |
| Jun 18, 26 | King Rachel K. | other | 14,180 |
| Jun 20, 26 | King Rachel K. | other | 18,880 |
| Jun 20, 26 | DOUGLAS RICHARD | other | 18,880 |
| Jun 18, 26 | DOUGLAS RICHARD | other | 21,270 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVAX coverage
Recent articles, reports, and earnings notes.
No research on NVAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVAX report →Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
marketbeat.com · Nov 17
Novavax to Participate in Jefferies London Healthcare Conference
prnewswire.com · Nov 11
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Nov 10
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
zacks.com · Nov 6
Novavax Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
prnewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.